Merck to Acquire Immune Design for its Technologies for $300M
Shots:
- Merck acquires Immune Design- in all stock transaction for $5.85/share in cash making total deal value ~ $300M. The transaction is expected to close in Q2’19
- The focus of the agreement is to develop and commercialize immune vaccines using Immune Design’s in vivo technologies i.e GLAAS and ZVex against cancer and infectious diseases
- GLA Adjuvant Systems (GLAAS) is an in vivo Glucopyranosyl Lipid A (GLA) based platform that binds TLR4 receptor activating DCs to produce cytokines and chemokines activating Th1-type immune response. ZVex is a delivery system designed for developing T-Cells targeting tumor cells
Ref: Merck | Image: Merck
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com